[1] Yabuki N, SASANO H, KATO K. Immunohistochemical study of DNA topoisomerase in human gastric disorders, 1996
[2] GOTLIEB W H, GOLDBERG I, WEISE B. Topoisomerase Ⅱimmunostaining as a prognostic marker for survival in ovarian cancer. 2001(1). doi:10.1006/gyno.2001.6208
[3] Provencio M, CORBACHO C, SALAS C. The topoisomerase Ⅱ alpha expression correlates with survival in patients with advanced Hodgkin' s lymphoma. 2003
[4] COLEMAN L W, BRONSTEIN I B, HOLDEN J A. Immunohistochemical staining for DNA topoisomerase Ⅰ,DNA topoisomerase Ⅱ alpha and p53 in gastric carcinomas. 2001(2A)
[5] 张春军, 孙晓波, 金锋. 多药耐药基因TopoⅡα mRNA在胃癌及其相邻正常组织中表达. 中国医科大学学报2003(4). doi:10.3969/j.issn.0258-4646.2003.04.021
[6] Kim R, OHI Y, INOUE H. Expression and relationship between topoisomerase Ⅰ and Ⅱ alpha genes in tumor and normal tissues in esophageal,gastric and colon cancers, 1999
[7] Nakopoulou L, LAZARIS A C, KAVANTZAS N. DNA topoisomerase Ⅱ-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. 2000(3). doi:10.1159/000055914
[8] 郑文莉, 谢兆霞, 唐果成. 急性白血病患者白血病细胞DNA拓扑异构酶Ⅱ活性与多药耐药的研究. 中华血液学杂志1998(9)
[9] Tanner B, PILCHH H, SCHAFFER U. Expression of c-erbB2 and topoisomerase Ⅱ alpha in relation to chemoresistance in ovarian cancer, 2002
[10] Di Leo A, GANCBERC D, LARSIMONT D. HER-2 ampli-fication and topoisomerase Ⅱ alpha gene aberrations as predictive markers in node-posotive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclopharnide,methotrexate,and 5-fluorouracil, 2002
[11] Campiglio M, SOMENZI G, OLGIATI C. Role of proliferation in HER2 status predicted reforse to doxorubicin. 2003. doi:10.1002/ijc.11113
[12] Villman K, STAHL E, LILJEGREN G. Topoisomerase Ⅱ-alpha expression in different cell cycle phases in fresh human breast carcinomas. 2002(5). doi:10.1038/modpathol.3880552
[13] Kizaki H, ONISHI Y. Topoisomerase Ⅱ in hibiter induced apoptsis in thymocytes and lymphoma cells. 1997. doi:10.1016/S0065-2571(96)00014-3
[14] Beck W T, MO Y Y, BHATU G. Cytoxic signaling by inhibitors of DNA topoisomerase Ⅱ. 2001. doi:10.1042/BST0290702
[15] Dhawan V, SWAFFAR D S. An unique paclitaxel mediated modulation of the catalytic captivity of topoisomerase Ⅱα. 1999. doi:10.1097/00001813-199904000-00008
[16] Brana M F, CACHO M, GRADILLASA. Intercalators as anticancer drugs, 2001
[17] Okada Y, TOSAKA A, NIMURA Y. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase Ⅱ alpha. 2001(1). doi:10.1016/S0378-1119(1)00554-6
[18] Wessel I, JENSEN L H, RENODON-CORNOERE A. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase Ⅱ alpha. 2002(1/3). doi:10.1016/S0014-5793(2)02805-3
[19] LOSHIYAMA M, FUJII H, KINEZAKI M. Correlation between Topo Ⅱα expression and chemsensitivity testing for Topo Ⅱ-targeting drug in gynaecologocal carcinomas. 2001(2A)
[20] Cardoso F, EURBECQ V, LARSIMONT D. Correlation between complete response to anthracycline-based chemtherapy and topoisomerase Ⅱ -alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. 2004(1)
[21] HERZOG C E, HOLMES K A, GEWIRTZ A. Absence topoisomerase Ⅱ beta in an amsacrine-resistant human leukemia cell line with mutant topoisomarase Ⅱ apha, 1998
[22] 赵智开, 董作仁, 王福旭. 拓扑异构酶Ⅱ与急性白血病预后和细胞周期的研究. 临床血液学杂志2002(1). doi:10.3969/j.issn.1004-2806.2002.01.002
[23] Lage H, DIETEL M. Multiple mechanisms confer different drugresistant phenotypes in pancreatic carcinoma cells. 2002(7). doi:10.1007/s00432-002-0349-y
[24] Ganapathi R, ZWELLING L, CONSTANTION A. Altered phosphory lation,biosynthes is and degradation of the 170 kDa isoform of topoisomerase Ⅱ in amcrine-resistant human leukemia cells. 1993. doi:10.1006/bbrc.1993.1554
[25] Matsumoto Y, TAKANO H, KUNISHIO K. Hypo-phosphorylation of topoisomerase Ⅱ alpha in etoposide(VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation, 2001 |
